HomeCompareLIAN vs VICI

LIAN vs VICI: Dividend Comparison 2026

LIAN yields 134.80% · VICI yields 6.57%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LIAN wins by $13.73M in total portfolio value
10 years
LIAN
LIAN
● Live price
134.80%
Share price
$0.32
Annual div
$0.43
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$14.72M
Annual income
$5,984,170.20
Full LIAN calculator →
VICI
VICI Properties Inc.
● Live price
6.57%
Share price
$27.12
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$988.8K
Annual income
$623,261.32
Full VICI calculator →

Portfolio growth — LIAN vs VICI

📍 LIAN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLIANVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LIAN + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LIAN pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LIAN
Annual income on $10K today (after 15% tax)
$11,457.68/yr
After 10yr DRIP, annual income (after tax)
$5,086,544.67/yr
VICI
Annual income on $10K today (after 15% tax)
$558.67/yr
After 10yr DRIP, annual income (after tax)
$529,772.12/yr
At 15% tax rate, LIAN beats the other by $4,556,772.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LIAN + VICI for your $10,000?

LIAN: 50%VICI: 50%
100% VICI50/50100% LIAN
Portfolio after 10yr
$7.85M
Annual income
$3,303,715.76/yr
Blended yield
42.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

LIAN
Analyst Ratings
1
Buy
1
Hold
1
Sell
Consensus: Buy
Altman Z
-2.4
Piotroski
2/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+16.5% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LIAN buys
0
VICI buys
0
No recent congressional trades found for LIAN or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLIANVICI
Forward yield134.80%6.57%
Annual dividend / share$0.43$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$14.72M$988.8K
Annual income after 10y$5,984,170.20$623,261.32
Total dividends collected$13.51M$948.4K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: LIAN vs VICI ($10,000, DRIP)

YearLIAN PortfolioLIAN Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$24,180$13,479.62$11,368$948.43+$12.8KLIAN
2$56,333$30,460.96$13,339$1,493.16+$43.0KLIAN
3$126,601$66,324.55$16,326$2,426.21+$110.3KLIAN
4$274,767$139,304.02$21,123$4,112.15+$253.6KLIAN
5$576,559$282,557.87$29,379$7,368.23+$547.2KLIAN
6$1,171,036$554,118.18$44,804$14,191.64+$1.13MLIAN
7$2,304,838$1,051,829.48$76,658$29,972.12+$2.23MLIAN
8$4,400,957$1,934,780.61$150,894$71,015.81+$4.25MLIAN
9$8,161,691$3,452,667.04$350,814$193,582.47+$7.81MLIAN
10$14,717,180$5,984,170.20$988,809$623,261.32+$13.73MLIAN

LIAN vs VICI: Complete Analysis 2026

LIANStock

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Full LIAN Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this LIAN vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LIAN vs SCHDLIAN vs JEPILIAN vs OLIAN vs KOLIAN vs MAINLIAN vs NNNLIAN vs EPRTLIAN vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.